Latest Articles
- ArticleSerum peptide reactivities may distinguish neuromyelitis optica subgroups and multiple sclerosisImke Metz, Tim Beißbarth, David Ellenberger, et al.February 02, 2016
- Clinical/Scientific NotesDegos disease mimicking primary vasculitis of the CNSSabrina Gmuca, Markus D. Boos, Amanda Treece, et al.February 02, 2016
- ArticlePatients with MS under daclizumab therapy mount normal immune responses to influenza vaccinationYen Chih Lin, Paige Winokur, Andrew Blake, et al.January 27, 2016
- ArticleTherapy with natalizumab is associated with high JCV seroconversion and rising JCV index valuesNicholas Schwab, Tilman Schneider-Hohendorf, Béatrice Pignolet, et al.January 27, 2016
- EditorialRising JCV-Ab index during natalizumab therapy for MSInauspicious for a highly efficacious drugAdil Javed, Anthony T. RederJanuary 27, 2016
- ArticleConverging mediators from immune and trophic pathways to identify Parkinson disease dementiaLih-Fen Lue, Christopher T. Schmitz, Noelle L. Snyder, et al.January 27, 2016
- ArticleCytokine profiles show heterogeneity of interferon-β response in multiple sclerosis patientsHarald Hegen, Indra Adrianto, Christopher J. Lessard, et al.January 27, 2016
- ArticleSerum lipid antibodies are associated with cerebral tissue damage in multiple sclerosisRohit Bakshi, Ada Yeste, Bonny Patel, et al.January 27, 2016
- Clinical/Scientific NotesAutopsy-proven demyelination associated with infliximab treatmentMichael J. Bradshaw, Bret C. Mobley, Jeffrey P. Zwerner, et al.January 27, 2016
- ArticleAlemtuzumab long-term immunologic effectTreg suppressor function increases up to 24 monthsStefania De Mercanti, Simona Rolla, Angele Cucci, et al.January 21, 2016
Pages
Advertisement